INDIVIDUAL ARTICLE: Real-World Clinical Case Series Utilizing Acneceuticals as Monotherapy, Adjunctive, or Maintenance Therapy for Acne Vulgaris
Journal of Drugs in Dermatology · 2025
DOI: 10.36849/jdd.08421 ↗At a glance
Fallbericht in Journal of Drugs in Dermatology, 2025. Written by Hilary Baldwin and 5 co-authors. Major MEDLINE topics: Acne Vulgaris, Dermatologic Agents, Nonprescription Drugs.
Abstract (original language)
BACKGROUND: Acne vulgaris is a common, multifactorial inflammatory skin disease for which there are many pharmacologic and procedural interventions. Recent publications have stressed the importance of quality skin care containing non-prescription actives (acneceuticals) in the treatment of this chronic disorder. Acne therapy is made more complicated by the diversity of presentation that includes age, gender, race, underlying skin type, product adherence, lesion morphology, and severity. METHODS: A panel of 6 dermatologists with expertise in the treatment of acne met twice for consensus conferences in March and November 2024. Discussion included the generation of 13 common disease presentations, the identification of potential cases to illustrate the presentations, and the design of 2-month case studies utilizing acneceuticals. Panelists chose new or established patients in their care who fit into the predetermined categories, provided them with the agreed-upon acneceuticals, and followed them for 2 months. RESULTS: Ten cases were chosen to comprise the most common therapeutic crossroads where pharmacologic or procedural interventions were not providing satisfactory control. This case study series included patients who were medication-intolerant, failing internet cures, not fully responsive to their current regimen, adult female acne patients with concomitant aging concerns, those needing maintenance therapy, and patients with issues regarding access to care. CONCLUSIONS: Acneceuticals were found to play an important role as monotherapy, adjunctive therapy, and maintenance therapy for acne patients. The 10 cases elucidated the ability of these over-the-counter (OTC) actives to improve patient care under several clinical scenarios. J Drugs Dermatol. 2025;24:6(Suppl 1):s3-14.
Subjects
MeSH terms (MEDLINE)
Substances
Cite
APA
Baldwin, H., Frey, C., Hebert, A., Ted Lain, E., Rieder, E., & Schlesinger, T. (2025). INDIVIDUAL ARTICLE: Real-World Clinical Case Series Utilizing Acneceuticals as Monotherapy, Adjunctive, or Maintenance Therapy for Acne Vulgaris. Journal of Drugs in Dermatology. https://doi.org/10.36849/jdd.08421
Vancouver
Baldwin H, Frey C, Hebert A, Ted Lain E, Rieder E, Schlesinger T. INDIVIDUAL ARTICLE: Real-World Clinical Case Series Utilizing Acneceuticals as Monotherapy, Adjunctive, or Maintenance Therapy for Acne Vulgaris. Journal of Drugs in Dermatology. 2025. doi:10.36849/jdd.08421
BibTeX
@article{Baldwin2025,
author = {Baldwin, Hilary and Frey, Cheri and Hebert, Adelaide and Ted Lain, Edward and Rieder, Evan and Schlesinger, Todd},
title = {INDIVIDUAL ARTICLE: Real-World Clinical Case Series Utilizing Acneceuticals as Monotherapy, Adjunctive, or Maintenance Therapy for Acne Vulgaris},
journal = {Journal of Drugs in Dermatology},
year = {2025},
doi = {10.36849/jdd.08421}
}
EUVIMED